Radó J P, Molnár Z, Hartai A, Gercsák G
Int J Clin Pharmacol Ther Toxicol. 1982 Nov;20(11):532-7.
Clinical, pharmacodynamic, and renal effects of a new diuretic, azosemide, were studied and compared with those of furosemide. Graded single intravenous (100-1600 mg) or peroral (100-400 mg) doses were administered to six patients with ascites due to liver cirrhosis without and during basic treatment with spironolactone. A standard peroral dose (160 mg) of both diuretics was found to have similar effectiveness. There was no difference in the time-course of action as determined on the basis of 24-h urine volume, sodium excretion, and osmolal clearance in four patients during basic treatment with spironolactone. However, azosemide appeared to be more effective than furosemide in those patients in whom a dose-response curve was established. Unlike furosemide, azosemide was much more effective when given intravenously than orally. Our study confirmed that azosemide is a "loop diuretic" with renal sites of action similar to those of furosemide. However, it has a higher efficiency, probably due to the steeper dose-response relationship.
对一种新型利尿剂阿佐塞米的临床、药效学及肾脏效应进行了研究,并与呋塞米进行了比较。对6例肝硬化腹水患者在未使用螺内酯及使用螺内酯进行基础治疗期间,分别静脉注射(100 - 1600毫克)或口服(100 - 400毫克)不同剂量的阿佐塞米。结果发现两种利尿剂的标准口服剂量(160毫克)疗效相似。在4例接受螺内酯基础治疗的患者中,根据24小时尿量、钠排泄量及渗透清除率判断,两种药物的作用时间过程无差异。然而,在那些建立了剂量反应曲线的患者中,阿佐塞米似乎比呋塞米更有效。与呋塞米不同,阿佐塞米静脉注射比口服有效得多。我们的研究证实,阿佐塞米是一种“袢利尿剂”,其肾脏作用部位与呋塞米相似。然而,它的效率更高,可能是由于剂量反应关系更陡峭。